Salarius Pharmaceuticals (SLRX) announces that on September 4, 2025 the Company received notification from The Nasdaq Stock Market that it has regained compliance with Listing Rule 5550(a)(2), the Minimum Bid Price Requirement. By meeting the Minimum Bid Price Requirement, Salarius has achieved one of the milestones in regaining compliance with all Nasdaq continued listing standards. As previously disclosed on August 27, 2025, Salarius has until October 20, 2025 to regain compliance with Nasdaq Listing Rule 5550(b)(1), the Equity Standard Requirement.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLRX:
- Salarius Pharmaceuticals Granted Nasdaq Compliance Extension
- Salarius Pharmaceuticals Files Prospectus for Stock Offering
- Decoy Therapeutics Reports Financial Downturn Amid Funding Challenges
- Salarius Pharmaceuticals Appoints New Acting CEO
- Upcoming Stock Splits This Week (August 18 to August 22) – Stay Invested